Polymyositis Market Analysis

Polymyositis (PM) is a rare idiopathic inflammatory myopathy characterized by symmetric proximal muscle weakness and elevated muscle enzymes. The exact cause of inflammatory myopathy is unclear, and in most cases, the immune system mistakenly attacks healthy body tissues, thus damaging muscle tissue in an autoimmune process.

According to Ann Rheum., the worldwide prevalence is estimated to 5–21.5 per 100,000, but only 3.8 per 100,000 in the US. Similarly, as per the Clark et al., the estimated prevalence is approximately 2 and 8 per 100,000 in Europe with peak Incidence of 60–69 years.

For more details on Polymyositis Market Insights, Epidemiology, and Pipeline Analysis, visit: https://www.delveinsight.com/report-store/polymyositis-market